Emergent Biosolutions Inc

EBS's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

EBS Growth rates comparisons

Emergent Biosolutions Inc 's sales fell by -21.34 % in the third quarter of 2025 from the same quarter a year ago. Ranking at No. 1812

Major Pharmaceutical Preparations industry recorded growth of revenues by 10.1 %

Emergent Biosolutions Inc 's net profit decreased by -55.4 % in third quarter of 2025 year on year, to $51 millions.

• More on EBS's Growth

EBS's Valuation comparisons

Emergent Biosolutions Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Emergent Biosolutions Inc PEG ratio is at -0.07 Company is currently trading with Price to Cash flow multiple of 7.14 in trailing twelve-month period.

Company

8.91

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 0.84.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 6.19.

• More on EBS's Valuation

Total Debt (Millions $)	663
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	493,063
Net Income/Employee (TTM) $	47,438
Receivable Turnover (TTM)	5.37
Tangible Book Value (Per Share $)	2.30

EBS's Valuation comparisons

Company

8.91

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 0.84.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 6.19.

Emergent Biosolutions Inc Price to Book Ratio is at 1.14 lower than Industry Avg. of 111.7. and higher than S&P 500 Avg. of 0.02

• More on EBS's Valuation

• Market Capitalization (Millions $)	662
• Shares Outstanding (Millions)	57
• Employees	1,600
• Revenues (TTM) (Millions $)	789
• Net Income (TTM) (Millions $)	76
• Cash Flow (TTM) (Millions $)	93
• Capital Exp. (TTM) (Millions $)	-12
• Total Debt (Millions $)	663
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	493,063
• Net Income/Employee(TTM) $	47,438
• Receivable Turnover Ratio (TTM)	5.37
• Tangible Book Value (Per Share $)	2.30

• Market Capitalization (Millions $)	662
• Shares Outstanding (Millions)	57
• Employees	1,600
• Revenues (TTM) (Millions $)	789
• Net Income (TTM) (Millions $)	76
• Cash Flow (TTM) (Millions $)	93
• Capital Exp. (TTM) (Millions $)	-12

EBS's Profitability Comparisons

Emergent Biosolutions Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in third quarter of 2025 to 33.1 % from 1.14 % in II. Quarter.

Emergent Biosolutions Inc net profit margin of 22.15 % is currently ranking no. 35 in Major Pharmaceutical Preparations industry, ranking no. 61 in Healthcare sector and number 723 in S&P 500.

Profitability by Segment
Total	22.15 %

	*Ratio*
• Capital Ratio (MRQ)	5.76
• Total Debt to Equity (MRQ)	1.14
• Tangible Leverage Ratio (MRQ)	6.77
• Asset Turnover Ratio (TTM)	0.55
• Inventory Turnover Ratio (TTM)	1.87

EBS's Profitability Comparisons

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.